招商引资

—

ENTERPRISE

AKR1B10简介

醛酮还原酶1B10 (AKR1B10，简称AKR) 是一种在正常人肝脏组织中极低表达，而在原发性肝细胞肝癌中高表达的新型分泌性蛋白，可从肿瘤细胞分泌进入血液循环。

在原发性肝细胞肝癌患者的血清中AKR1B10含量显著升高，而且与患者预后相关，是原发性肝癌一个新型的、高特异性与灵敏度的血清蛋白标记物。

大规模多中心临床研究

在中国医学科学院北京协和医院、湖南省人民医院、湖南省肿瘤医院、南华大学附属第一医院开展，有效样本数量达近3000例，研究证实AKR1B10是一种新型有效的血清标记物，可用于检测肝细胞肝癌(HCC)和早期HCC，优于AFP。

AKR1B10

Aldo-keto reductase 1B10 (AKR1B10 or AKR) is a new secretory protein, which is expressed at a very low level in normal human liver tissues, but highly expressed in hepatocellular carcinoma (HCC). AKR1B10 can be secreted from tumor cells into the blood circulation.

AKR1B10 is specifically increased in the serum of HCC patients and correlated with the prognosis of patients, being a new serum protein marker of HCC with high specificity and sensitivity.

Large scale multicenter clinical study

A multicentral clinical study with a cohort of approximate 3,000 subjects, carried out in Peking Union Medical College Hospital Chinese Academy of Medical Sciences, Hunan Provincial People's Hospital, Hunan Cancer Hospital, and the First Affiliated Hospital Nanhua University, demonstrated that AKR1B10 is a new and effective serum marker of HCC, which can be used for detection of HCC and early HCC, with better diagnostic performance than AFP.

产品中心

—

PRODUCTS

我们的服务

SERVICES WE DO